Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical.
Cell Therapeutics Inc, under license from the MD Anderson Cancer Center and in collaboration with Chugai Pharmaceutical Co Ltd (the Japanese subsidiary of Roche), is developing paclitaxel poliglumex, an intravenous poly-(alpha-L-glutamic acid) conjugate of paclitaxel for the potential treatment of solid tumors.